Barrett esophagus has many identifiable clinical features, and endoscopic findings that mimic barrett esophagus in the absence of GER can be life-threatening and require prompt medical attention.
This condition has no single cause or explanation, and has multiple possible causes that can interact in an individual. A small number of people are affected by this condition, and the exact cause is unknown.\n
The diagnosis of BE may be missed, particularly considering that BE is a disorder that affects men at least 10 years earlier than BE. In fact, a subset of patients with BE were only identified based on their previous history with gastroesophageous reflux.
Fewer than 200,000 cases of Barrett's esophagus are diagnosed in the United States each year. More than half of patients with a diagnosis of BE are female, and about one in twenty (5%) have a history of alcohol abuse. A history of BE is not strongly associated with any other major comorbidities and correlates more weakly with age.
The medical management of Barrett esophagus is aimed at optimizing the long-term outcome of esophageal healing and prevention of the development of Barrett's esophagus. There is limited evidence that the treatment of esophageal strictures/reflux esophagitis improves the long-term esophageal healing outcomes.
In conclusion, many (approximately 70%) of patients with Barrett esophagus can expect recovery of a normal esophagus at 3 years of follow-up. The cause of the refluxate esophagus may be the underlying cause of the BE. Patients who initially had BE and who are diagnosed with BE later, ie, 4 to 8 years after the onset of BE, may not have BE at 3 years of follow-up.
Results from a recent paper of this study suggest that the cryo balloon is effective in preventing new or restenotic strictures in the long term. The cryotherapy also achieves adequate dilatation of the strictures.
Treatments that aim to prevent [reflux esophagitis] are currently being used ("i.e." fundoplication and proton-pump inhibitors). While there are few controlled trials comparing fundoplication/proton-pump inhibitors with new treatments, we are confident that [power] will provide your clinician with recent evidence. New treatments are now available in the United States and Europe, but none have shown a positive response in randomized controlled trials. Therefore, additional work is needed for these new treatments to be recognized as standard of care.
These data do not support the view that there is a genetic component to BE and, therefore, suggest that factors other than genetics contribute to this complication.
The chance of developing Barrett esophagus depends on a number of individual factors. However, there was a statistically significant difference in the prevalence of Barrett esophagus among patients with esophageal adenocarcinoma, when compared with the prevalence of Barrett esophagus in patients with reflux disease and/or esophageal squamous cell neoplasia.
There's not enough research to establish whether medical treatments like gastric electrical stimulation and botulinum toxin injections help alleviate the symptoms of the heartburn and acid reflux associated with Barrett's esophagus. Overall, the research suggests Barrett's esophagus does cause significant discomfort but does not typically pose immediate health risks associated with esophageal cancer. However, it is necessary to note that the studies referenced above were limited in terms of overall quality, so there may be more research needed. It's important to remember that for Barrett's esophagus to develop into esophageal cancer, most experts agree that it must be present for 10 years and in other cases, the esophagus may already have metaplastic changes.